Clinical Evaluation Outsourcing: What You Actually Risk

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This scenario repeats across the industry. Outsourcing clinical evaluation work has become standard practice under MDR. The workload is heavy. The expertise is scarce. The pressure to submit is constant.

But outsourcing is not just a procurement decision. It changes how clinical evaluation is performed, how responsibility is distributed, and how easily things can go wrong.

I have reviewed reports written by external consultants, internal teams, and hybrid models. I have seen what works and what consistently fails. The decision to outsource is never neutral. It has consequences for quality, for timelines, and for regulatory outcomes.

Why Manufacturers Outsource Clinical Evaluation

The reasons are practical. Most medical device manufacturers do not have a full-time clinical evaluation expert on staff. The skillset required combines medical knowledge, regulatory understanding, literature review methodology, and technical device expertise.

Under MDR Article 61 and Annex XIV, the clinical evaluation must be performed or verified by someone with appropriate qualifications and experience. For many companies, this means bringing in external consultants.

There are also capacity issues. A single clinical evaluator may need to cover multiple device families, legacy products being recertified, and new product submissions. Outsourcing creates flexibility.

But flexibility comes with tradeoffs.

The Real Advantages of Outsourcing

When done correctly, outsourcing brings real value.

First, access to specialized expertise. A good clinical evaluation consultant has worked across multiple device types, multiple therapeutic areas, and multiple Notified Bodies. They know what reviewers expect. They know which arguments hold and which do not.

Second, efficiency in literature review. An experienced consultant can structure a search strategy, screen hundreds of articles, and extract relevant data faster than someone doing it for the first time. This matters when timelines are tight.

Third, objective perspective. An external consultant is not embedded in the company culture. They can challenge assumptions about device performance, question equivalence claims, and push back on insufficient data. This independence improves quality.

But these advantages only materialize if the outsourcing is structured correctly.

Where Outsourcing Typically Succeeds

Outsourcing works best for well-defined tasks with clear boundaries. For example, conducting a systematic literature review according to a predefined protocol. Or drafting the state of the art section based on agreed sources.

It also works when the consultant has direct access to technical documentation, post-market data, and internal subject matter experts. The quality of the output depends on the quality of the input.

And it works when there is continuity. A consultant who has worked with the same manufacturer over multiple projects understands the device portfolio, the regulatory history, and the clinical context. This reduces errors and miscommunication.

The Hidden Risks No One Talks About

Now the other side.

The most common failure is scope misalignment. The manufacturer assumes the consultant will produce a complete, submission-ready CER. The consultant assumes they are providing a draft that requires internal validation and completion.

This misalignment shows up in missing sections, incomplete risk-benefit analysis, or lack of device-specific clinical data. The manufacturer discovers the gaps too late. The consultant considers the work complete.

Another risk is consultant turnover. A consultant starts the work, then moves to another project or another company. A new consultant takes over without full context. The clinical evaluation loses coherence. Assumptions are not questioned. Errors are not caught.

Then there is the issue of medical and scientific validity. Some consultants write well but lack deep clinical expertise in the relevant therapeutic area. They can structure a document, but they cannot critically appraise evidence or interpret clinical outcomes. The report looks complete but lacks substance.

The Accountability Gap

Here is the structural problem. The consultant is contractually responsible for delivering a document. The manufacturer is legally responsible for the clinical evaluation conclusions under MDR Article 10(4).

If the CER is deficient, the manufacturer cannot claim ignorance. The Notified Body does not care who wrote the report. They care whether it meets Annex XIV requirements.

This creates a gap. The manufacturer may not have the expertise to validate the consultant’s work. The consultant may not have full visibility into the manufacturer’s data. The result is a report that satisfies neither party completely.

Best Practices for Outsourcing Clinical Evaluation

If you outsource, structure it correctly from the beginning.

Define the Scope in Detail

Do not rely on a one-page statement of work. Specify exactly what the consultant will deliver. Which sections of the CER. Which databases for literature search. Which appraisal methodology. Which version of the clinical evaluation plan they will follow.

Specify what the manufacturer will provide. Technical documentation. Post-market data. Access to design engineers or clinicians. Timelines for feedback.

Specify the review process. How many rounds of revision. Who validates the final content. Who signs off on the conclusions.

Select for Clinical Competence, Not Just Regulatory Experience

A consultant who understands MDR structure but lacks clinical judgment cannot perform a meaningful appraisal. Look for someone with medical or scientific background in the relevant area. Check their track record with similar devices.

Ask for examples of previous CERs they have written. Not full documents, but excerpts showing how they analyze clinical data, how they assess safety signals, how they justify equivalence.

Maintain Direct Involvement

Do not treat the consultant as a black box. Involve them in internal meetings. Give them access to subject matter experts. Walk them through complaint data and vigilance reports.

Review drafts early. Do not wait until the final version to discover misunderstandings. Provide feedback on content, not just formatting.

And assign an internal owner. Someone who understands both the device and the clinical evaluation requirements. Someone who can validate the consultant’s work before it goes to the Notified Body.

Build Institutional Memory

If you work with the same consultant over time, document the process. Create templates. Agree on appraisal criteria. Standardize literature search protocols.

This reduces inefficiency and prevents the same questions from being asked on every project. It also makes onboarding new team members easier.

If the consultant leaves, you have a knowledge base to hand over to their replacement.

When Outsourcing Is the Wrong Choice

Not every situation calls for outsourcing.

If the device is investigational or highly innovative, the clinical evaluation requires deep involvement from the development team. An external consultant cannot substitute for internal clinical expertise in these cases.

If post-market data is complex or scattered across multiple sources, an internal team may be better positioned to synthesize it. The consultant does not have the same access or context.

If the manufacturer is building long-term clinical evaluation capability, outsourcing everything delays that development. There is value in learning by doing, even if it takes longer initially.

The Hybrid Model

Many manufacturers are moving toward a hybrid approach. The consultant handles literature review, state of the art, and document structure. The internal team handles device-specific appraisal, post-market data analysis, and PMCF planning.

This model balances efficiency with accountability. It also builds internal capability over time.

But it requires coordination. Clear handoffs. Aligned timelines. Regular communication.

When the hybrid model works, it produces stronger clinical evaluations than either pure outsourcing or pure internal work.

Final Consideration

Outsourcing clinical evaluation is not inherently good or bad. It is a tool. Like any tool, it works when used correctly and fails when misapplied.

The key is to recognize what you are outsourcing and what you are keeping. You can outsource the writing. You cannot outsource the clinical judgment. You can outsource the literature search. You cannot outsource the responsibility.

The Notified Body will assess the clinical evaluation on its content, not on who wrote it. If the appraisal is weak, if the data is incomplete, if the conclusions are unsupported, the CER fails. The contract with the consultant does not change that outcome.

So if you outsource, do it with eyes open. Define the scope. Stay involved. Validate the work. And never assume that paying someone else makes the problem go away.

Because in clinical evaluation, the problem is never just the document. The problem is whether the evidence supports safe use. And that question cannot be outsourced.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.